Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients

by Marieke van Son, M.D., Max Peters, M.D., Ph.D., Marinus Moerland, Ir., Ph.D., Sandrine van de Pol, M.D., Wietse Eppinga, M.D., Jan Lagendijk, Prof., Jochem van der Voort van Zyp, Ass. prof.
Published 2021-03-01